China’s National Medical Products Administration accepted Novo Nordisk’s marketing application for the oral version of Wegovy. This marks a critical step toward launching the weight-loss treatment in the world’s second-largest pharmaceutical market.
The move positions Novo Nordisk to compete with Eli Lilly, which has also submitted an application for an oral weight-loss drug in China. Oral tablets are expected to expand the market by attracting patients who prefer them over injectable versions.
Projections indicate that over 65% of China’s population could be overweight or obese by 2030. This trend highlights a substantial commercial opportunity for obesity treatments in the region.